American Journal of Cardiovascular Drugs

, Volume 7, Issue 6, pp 393–398

The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications

  • Gemma Tremolada
  • Rosangela Lattanzio
  • Gabriella Mazzolari
  • Gianpaolo Zerbini
Leading Article


During the last few years, the incidence of microvascular complications in diabetes mellitus has rapidly increased as a consequence of both an increase in incidence of type 2 and type 1 diabetes mellitus.

The pathogenesis of diabetic microvascular complications is still largely unknown. Among the many hypotheses, a dysfunction in angiogenesis has been suggested as a common origin for retinopathy, nephropathy, and neuropathy. Based on this hypothesis, inhibition of vascular endothelial growth factor (VEGF) has been tested as a potential therapeutic approach to prevent and cure diabetic microvascular complications. Several VEGF inhibitors are currently under evaluation or are approved for the treatment of wet age-related macular degeneration and macular edema. These include inhibitors of intracellular transcription of VEGF (e.g. bevasiranib), inhibitors of extracellular VEGF (e.g. pegaptanib), inhibitors of VEGF receptor expression (e.g. aflibercept [VEGF-TRAP]) and inhibitors of the intracellular signaling cascade activating VEGF (e.g. midostaurin).

According to the existing evidence base, although inhibition of VEGF results in a better outcome in the case of diabetic retinopathy and also, despite some discrepant results, in the case of diabetic nephropathy, there is no final confirmation that VEGF inhibition is a valid approach for diabetic neuropathy. The latter complication actually, in line with other chronic neuropathies, seems to improve with stimulation of angiogenesis through increased expression of VEGF.


  1. 1.
    Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 77: S113–9.CrossRefGoogle Scholar
  2. 2.
    Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779–802.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–76.PubMedCrossRefGoogle Scholar
  5. 5.
    Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Li X, Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 2001; 33: 421–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Shibuya M. Vascular endothelial growth factor receptor-2: its unique signalling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 1995; 376: 62–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70.PubMedCrossRefGoogle Scholar
  10. 10.
    Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282: 946–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Mura M, dos Santos CC, Stewart D, et al. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol 2004; 97: 1605–17.PubMedCrossRefGoogle Scholar
  12. 12.
    Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853–65.PubMedGoogle Scholar
  14. 14.
    Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999; 13: 9–22.Google Scholar
  15. 15.
    Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal out-growth through the flk-1 receptor. Eur J Neurosci 2000; 12: 4243–54.PubMedCrossRefGoogle Scholar
  16. 16.
    Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26: 943–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Kempen JH, O’Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Klein R, Klein BE, Moss SE. The Winsconsin epidemiology study of diabetic retinopathy: a review. Diabetes Metab Rev 1989; 5: 559–70.PubMedCrossRefGoogle Scholar
  20. 20.
    Diabetic retinopathy study group. Preliminary report on effects of photocoagulation theraphy. Am J Ophthalmol 1976; 81: 383–96.Google Scholar
  21. 21.
    Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98: 766–85.Google Scholar
  22. 22.
    Shimura M, Yasuda K, Nakazawa T, et al. Quantifying alterations of macular thickness before and after panretinal photocoaculation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110: 2386–94.PubMedCrossRefGoogle Scholar
  23. 23.
    Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279–99.PubMedCrossRefGoogle Scholar
  24. 24.
    Stitt AW, Simpson DA, Boocock C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol 1998; 186: 306–12.PubMedCrossRefGoogle Scholar
  25. 25.
    Boulton M, Foreman D, Williams G, et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002; 43: 849–57.PubMedGoogle Scholar
  27. 27.
    Sheetz MJ, King LK. Molecular understanding of hyperglicemia’s adverse effects for diabetic complications. JAMA 2002; 288: 2579–88.PubMedCrossRefGoogle Scholar
  28. 28.
    Mill JW, Adamis AP, Aiello LP. Vascular endothelium growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997; 13: 37–50.CrossRefGoogle Scholar
  29. 29.
    Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelium growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelium growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epitheliumderived factor and vascular endothelium growth factor are related to diabetic macular edema. Ophthalmology 2006; 113: 294–301.PubMedCrossRefGoogle Scholar
  32. 32.
    Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445–50.PubMedGoogle Scholar
  33. 33.
    Shen J, Samul R, Silva RL, et al. Suppresion of ocular neovascularitazion with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225–34.PubMedCrossRefGoogle Scholar
  34. 34.
    Macugen Diabetic Study group. A phase II randomised double-masked trial of pegabtanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmolgy 2005; 112: 1747–57.CrossRefGoogle Scholar
  35. 35.
    Adamis AP, Altaweel M, Bressler NM, et al., for the Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Avery RL. Regression of retinal and iris neovascolarization after intravitreal bevacizumeb (Avastin) treatment. Retina 2006; 26: 356–7.CrossRefGoogle Scholar
  38. 38.
    Spaide RF, Fischer YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemmorage. Retina 2006; 26: 275–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Avery RL, Pearlman J, Pieramici DJ, et al. Intraviteal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 363–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Jager RD, Aiello LP, Patel SC, et al. Risk of intravenous injection: a comprehensive review. Retina 2004; 24: 676–98.PubMedCrossRefGoogle Scholar
  41. 41.
    Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegabtanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–16.PubMedCrossRefGoogle Scholar
  42. 42.
    Chong NV, Adewoyin T. Intravitreal injection: balancing the risks. Eye 2007; 21: 313–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Saishin Y, Sayshin Y, Takahashi K, et al. VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of blood-retinal barrier. J Cell Physiol 2003; 195: 241–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Ryan AJ, Wedge SR. ZD647: a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005; 92 Suppl. 1: S6–13.PubMedCrossRefGoogle Scholar
  45. 45.
    Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389–400.PubMedCrossRefGoogle Scholar
  46. 46.
    Hess-Stumpp H, Haberey M, Thierauch KH. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 2005; 6: 550–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005; 10: 382–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelium growth factorinduced retinal permeability is mediate by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997; 46: 1473–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Danis RP, Bingaman DP, Jirousek M, et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PCK β inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171–9.PubMedGoogle Scholar
  50. 50.
    The PCK-DRS Study group. The effect of ruboxistaurin on visual loss in patients with moderately severe to severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β inhibitor Diabetic Retinopathy Study (PCK-DRS) multicenter randomised clinical trial. Diabetes 2005; 54: 2188–97.CrossRefGoogle Scholar
  51. 51.
    Aiello LP, Clermont A, Arora V, et al. Inhibition of PCK β by oral administration of ruboxistaurine is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006; 47: 86–92.PubMedCrossRefGoogle Scholar
  52. 52.
    Eggers PW. Effect of transplantation on the Medicare endstage renal disease program. N Engl J Med 1988; 318: 223–6.PubMedCrossRefGoogle Scholar
  53. 53.
    USRDS. Annual Data Report 1994. Incidence and causes of treated ESRD. Am J Kidney Dis 1994; 24: S48–56.Google Scholar
  54. 54.
    Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type I (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 290–6.CrossRefGoogle Scholar
  55. 55.
    Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992; 42: 1457–61.PubMedCrossRefGoogle Scholar
  56. 56.
    Khamaisi M, Schrijvers BF, De Vriese AS, et al. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 2003; 8: 1427–30.CrossRefGoogle Scholar
  57. 57.
    Simon M, Grone HJ, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 268: F240–50.PubMedGoogle Scholar
  58. 58.
    Simon M, Rocckl W, Hornig C, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localisation and [125I]VEGF binding sites. J Am Soc Nephrol 1998; 9: 1032–44.PubMedGoogle Scholar
  59. 59.
    Brenchley PE. VEGF/VPF: a modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 1996; 9: 10–7.Google Scholar
  60. 60.
    Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229–39.PubMedCrossRefGoogle Scholar
  61. 61.
    Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579–88.PubMedCrossRefGoogle Scholar
  62. 62.
    Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 1993; 36: 189–94.PubMedCrossRefGoogle Scholar
  63. 63.
    de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993–1000.PubMedGoogle Scholar
  64. 64.
    Sung SH, Ziyadeh FN, Wang A, et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093–104.PubMedCrossRefGoogle Scholar
  65. 65.
    Schrijvers BF, Flyvbjerg A, Tilton RG, et al. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 2006; 21: 324–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004; 53: 1831–40.PubMedCrossRefGoogle Scholar
  67. 67.
    Schrijvers BF, De Vriese AS, Tilton RG, et al. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res 2005; 37: 21–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Vinik AI, Mitchell BD, Leichter SB, et al. Epidemiology of the complications of diabetes. In: Leslie RDG, Robbins DC, editors. Diabetes: clinical science in practice. Cambridge: Cambridge University Press, 1994: 221–87.Google Scholar
  69. 69.
    Skold MK. VEGF and VEGF receptor expression after experimental brain contusion in rat. J Neurotrauma 2005; 22: 353–67.PubMedCrossRefGoogle Scholar
  70. 70.
    Mukouyama YS, Gerber HP, Ferrara N, et al. Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development 2005; 132: 941–52.PubMedCrossRefGoogle Scholar
  71. 71.
    Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioassays 2004; 26: 943–54.CrossRefGoogle Scholar
  72. 72.
    Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083–92.PubMedCrossRefGoogle Scholar
  73. 73.
    Murakami T, Arai M, Sunada Y, et al. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J Gene Med 2006; 8: 773–81.PubMedCrossRefGoogle Scholar
  74. 74.
    Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 2000; 6: 405–13.PubMedCrossRefGoogle Scholar
  75. 75.
    Chattopadhyay M, Krisky D, Wolfe D, et al. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther 2005; 12: 1377–84.PubMedCrossRefGoogle Scholar
  76. 76.
    Price SA, Dent C, Duran-Jimenez B, et al. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 2006; 55: 1847–54.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Gemma Tremolada
    • 1
  • Rosangela Lattanzio
    • 1
  • Gabriella Mazzolari
    • 2
  • Gianpaolo Zerbini
    • 2
    • 3
  1. 1.Department of Ophthalmology and Visual SciencesSan Raffaele Scientific InstituteMilanItaly
  2. 2.Renal Pathophysiology UnitSan Raffaele Scientific InstituteMilanItaly
  3. 3.Division of MedicineSan Raffaele Scientific InstituteMilanItaly

Personalised recommendations